# ResMed Inc. (RMD) FY2027 Q1 Balance Sheet

- Company: ResMed Inc. (RMD)
- Period: As of 2026-09-30
- Filing: Q1 FY2027 10-Q, filed 2026-10-30, accession number 0000943819-26-000089
- Page: https://plicit.ai/financials/rmd/fy2027-q1-balance-sheet
- Chart image: https://plicit.ai/charts/rmd-fy2027-q1-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-09-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 8,211,811,000 US dollars
- **Current assets**: 3,508,921,000 US dollars
- **Non-current assets**: 4,702,890,000 US dollars
- **Liabilities**: 2,264,121,000 US dollars
- **Current liabilities**: 1,324,220,000 US dollars
- **Non-current liabilities**: 939,901,000 US dollars
- **Equity**: 5,947,690,000 US dollars
- **Inventories**: 1,021,358,000 US dollars
- **Cash and cash equivalents**: 1,010,742,000 US dollars
- **Accounts receivable, net of allowances of $27,103 and $25,839 at September 30, 2026 and June 30, 2026, respectively**: 972,498,000 US dollars
- **Prepaid expenses and other current assets**: 504,323,000 US dollars
- **Assets held for sale**: 0 US dollars
- **Goodwill**: 2,908,232,000 US dollars
- **Property, plant and equipment, net**: 601,787,000 US dollars
- **Other intangible assets, net**: 442,681,000 US dollars
- **Deferred income taxes**: 344,845,000 US dollars
- **Prepaid taxes and other non-current assets**: 208,657,000 US dollars
- **Operating lease right-of-use assets**: 196,688,000 US dollars
- **Accrued expenses**: 480,166,000 US dollars
- **Accounts payable**: 320,677,000 US dollars
- **Deferred revenue**: 171,647,000 US dollars
- **Income taxes payable**: 160,228,000 US dollars
- **Short-term debt, net**: 159,975,000 US dollars
- **Operating lease liabilities, current**: 31,527,000 US dollars
- **Liabilities held for sale**: 0 US dollars
- **Other long-term liabilities**: 283,965,000 US dollars
- **Long-term debt, net**: 249,629,000 US dollars
- **Deferred revenue**: 174,209,000 US dollars
- **Operating lease liabilities, non-current**: 169,447,000 US dollars
- **Deferred income taxes**: 62,651,000 US dollars
- **Retained earnings**: 7,578,580,000 US dollars
- **Additional paid-in capital**: 2,133,418,000 US dollars
- **Common stock, $0.004 par value, 350,000,000 shares authorized; 191,080,699 issued and 140,639,154 outstanding at September 30, 2026 and 191,037,523 issued and 144,239,563 outstanding at June 30, 2026**: 764,000 US dollars
- **Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued**: 0 US dollars
- **Treasury stock, at cost, 50,441,545 shares at September 30, 2026 and 46,798,043 shares at June 30, 2026**: negative 3,633,335,000 US dollars
- **Accumulated other comprehensive loss**: negative 131,737,000 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.

## Key Takeaways

- Shareholders' equity fell $637.70 M to $5.95 B, while retained earnings rose $323.46 M.
- Shares it bought back, booked as treasury stock, rose $854.74 M in one quarter.
- Current assets still cover current liabilities, but the cover slipped from 3.10 to 2.65 times.
- Debt fell 38% to $409.60 M, and the $1.01 B cash pile now covers all of it.
- A $19 M restructuring charge hit the quarter, and $12 M of restructuring costs is still unpaid.

## The Unvarnished Truth

### ResMed's cash cushion fell $458.49 M in a single quarter.

ResMed's cash cushion fell $458.49 M in one quarter, to $1.01 B from $1.47 B. The bigger shock is on the owners' side of the page. Shareholders' equity dropped $637.70 M, to $5.95 B, even though retained earnings, the profit kept over the years, still rose $323.46 M. The biggest single move is treasury stock, the shares ResMed bought back and holds, which rose $854.74 M in one quarter. Set against the $418.41 M of profit the quarter earned, that buyback was about twice as large.

Why buy back that much? The filing's explanation runs through the share count. ResMed repurchased 3.6 million shares for $855 million in the quarter. It also says it used part of the proceeds from selling its MatrixCare business to pay the $450 million due under an accelerated buyback agreement. The sale also lifts reported profit: its $62 million gain sits inside net income, while the $470 million of cash came in through investing, not through earnings. Inventory tells a different tale: finished goods rose $72.08 M in the quarter, and the filing says only that higher inventory levels are partially related to the expansion of its supply chain.

ResMed still has $2.51 B of cash and available credit, enough for its near-term bills on paper. The cushion is thinner now, and the $1.5 B revolving credit facility it can still draw on, undrawn today, terminates on June 29, 2027. Finished goods are the open question: they must sell through before they become cash, and the filing does not say how much of the build is planned stock. Will that stock turn into cash over the next few quarters, or come back as write-downs?

## Intelligent Insights for Investors

### How much debt does ResMed carry?

ResMed owed $409.60 M of debt on September 30, 2026, down 38% from $659.37 M at the last year-end. Its $1.01 B of cash would cover all of it.

### How much cash does ResMed have on hand?

It held $1.01 B of cash on September 30, 2026, enough for 76% of what it owes within a year. At the last year-end, $1.47 B covered 105% of the bills then due within a year.

### How much of ResMed's assets come from paying for acquisitions?

About two-fifths of its assets came from paying for businesses. Goodwill, the premium paid above the value of the businesses it bought, and other intangible assets came to $3.35 B, or 41% of assets on September 30, 2026, against 38% at the last year-end.

## Intelligent Insights for Lenders

### What does ResMed owe, and to whom?

Of the $2.26 B ResMed owed on September 30, 2026, 18% was owed to lenders. Another 37% sits in lines that mix several kinds of creditor or are labeled other.

## Intelligent Insights for Employees

### How much unpaid severance and exit cash does ResMed still owe?

ResMed still owed $12.00 M of restructuring costs, such as severance and exit costs, on September 30, 2026. The note lists the $19 M quarter's charges as severance, one-time termination benefits and software impairment, and says it does not expect material expense left under those arrangements.

## Intelligent Insights for Customers

### How much have customers paid ResMed in advance?

Customers had paid ResMed $345.86 M in advance on September 30, 2026, for products and services it has not yet delivered. That money is already in hand; it becomes revenue as ResMed delivers.
